Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 190

1.

PAX8-GLIS3 gene fusion is a pathognomonic genetic alteration of hyalinizing trabecular tumors of the thyroid.

Marchiò C, Da Cruz Paula A, Gularte-Merida R, Basili T, Brandes A, da Silva EM, Silveira C, Ferrando L, Metovic J, Maletta F, Annaratone L, Pareja F, Rubin BP, Hoschar AP, De Rosa G, La Rosa S, Bongiovanni M, Purgina B, Piana S, Volante M, Weigelt B, Reis-Filho JS, Papotti M.

Mod Pathol. 2019 Jul 4. doi: 10.1038/s41379-019-0313-x. [Epub ahead of print]

PMID:
31273314
2.

V211D mutation in MEK1 causes resistance to MEK inhibitors in colon cancer.

Gao Y, Maria A, Na N, Da Cruz Paula A, Gorelick AN, Hechtman JF, Carson J, Lefkowitz RA, Weigelt B, Taylor BS, Zhao H, Reis-Filho JS, de Stanchina E, Rosen N, Yao Z, Yaeger R.

Cancer Discov. 2019 Jun 21. pii: CD-19-0356. doi: 10.1158/2159-8290.CD-19-0356. [Epub ahead of print]

PMID:
31227518
3.

Exploring Collagen Parameters in Pure Special Types of Invasive Breast Cancer.

Natal RA, Paiva GR, Pelegati VB, Marenco L, Alvarenga CA, Vargas RF, Derchain SF, Sarian LO, Franchet C, Cesar CL, Schmitt FC, Weigelt B, Vassallo J.

Sci Rep. 2019 May 22;9(1):7715. doi: 10.1038/s41598-019-44156-9.

4.

Secretory carcinoma of the breast: clinicopathologic profile of 14 cases emphasising distant metastatic potential.

Hoda RS, Brogi E, Pareja F, Nanjangud G, Murray MP, Weigelt B, Reis-Filho JS, Wen HY.

Histopathology. 2019 Apr 23. doi: 10.1111/his.13879. [Epub ahead of print]

PMID:
31012486
5.

Solid pseudopapillary neoplasms of the pancreas are dependent on the Wnt pathway.

Selenica P, Raj N, Kumar R, Brown DN, Arqués O, Reidy D, Klimstra D, Snuderl M, Serrano J, Palmer HG, Weigelt B, Reis-Filho JS, Scaltriti M.

Mol Oncol. 2019 Apr 10. doi: 10.1002/1878-0261.12490. [Epub ahead of print]

6.

A combinatorial biomarker predicts pathologic complete response to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2+ breast cancer.

Veeraraghavan J, De Angelis C, Mao R, Wang T, Herrera S, Pavlick AC, Contreras A, Nuciforo P, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Wolff AC, Krop IE, Fuqua SAW, Prat A, Hilsenbeck SG, Weigelt B, Reis-Filho JS, Gutierrez C, Osborne CK, Rimawi MF, Schiff R.

Ann Oncol. 2019 Mar 23. pii: mdz076. doi: 10.1093/annonc/mdz076. [Epub ahead of print]

PMID:
30903140
7.

Micropapillary variant of mucinous carcinoma of the breast shows genetic alterations intermediate between those of mucinous carcinoma and micropapillary carcinoma.

Pareja F, Selenica P, Brown DN, Sebastiao APM, da Silva EM, Da Cruz Paula A, Del A, Fu L, Weigelt B, Brogi E, Reis-Filho JS, Wen HY.

Histopathology. 2019 Jul;75(1):139-145. doi: 10.1111/his.13853. Epub 2019 Jun 13.

PMID:
30843622
8.

Genomic analysis of recurrences and high-grade forms of polymorphous adenocarcinoma.

Sebastiao APM, Pareja F, Kumar R, Brown DN, Silveira C, da Silva EM, Lee JY, Del A, Katabi N, Chiosea S, Weigelt B, Reis-Filho JS, Seethala RR.

Histopathology. 2019 Mar 7. doi: 10.1111/his.13854. [Epub ahead of print]

PMID:
30843621
9.

Massively parallel sequencing analysis of benign melanocytic naevi.

Lozada JR, Geyer FC, Selenica P, Brown D, Alemar B, Merghoub T, Berger MF, Busam KJ, Halpern AC, Weigelt B, Reis-Filho JS, Hollmann TJ.

Histopathology. 2019 Jul;75(1):29-38. doi: 10.1111/his.13843. Epub 2019 May 24.

PMID:
30791119
10.

Assessment of HMGA2 and PLAG1 rearrangements in breast adenomyoepitheliomas.

Pareja F, Geyer FC, Brown DN, Sebastião APM, Gularte-Mérida R, Li A, Edelweiss M, Da Cruz Paula A, Selenica P, Wen HY, Jungbluth AA, Varga Z, Palazzo J, Rubin BP, Ellis IO, Brogi E, Rakha EA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2019 Jan 18;5:6. doi: 10.1038/s41523-018-0101-7. eCollection 2019.

11.

The Genomic Landscape of Mucinous Breast Cancer.

Pareja F, Lee JY, Brown DN, Piscuoglio S, Gularte-Mérida R, Selenica P, Da Cruz Paula A, Arunachalam S, Kumar R, Geyer FC, Silveira C, da Silva EM, Li A, Marchiò C, Ng CKY, Mariani O, Fuhrmann L, Wen HY, Norton L, Vincent-Salomon A, Brogi E, Reis-Filho JS, Weigelt B.

J Natl Cancer Inst. 2019 Jan 11. doi: 10.1093/jnci/djy216. [Epub ahead of print]

PMID:
30649385
12.

Somatic genetic alterations in synchronous and metachronous low-grade serous tumours and high-grade carcinomas of the adnexa.

Murali R, Selenica P, Brown DN, Cheetham RK, Chandramohan R, Claros NL, Bouvier N, Cheng DT, Soslow RA, Weigelt B, McCluggage WG.

Histopathology. 2019 Mar;74(4):638-650. doi: 10.1111/his.13796. Epub 2019 Jan 15.

PMID:
30565721
13.

Recurrent MED12 exon 2 mutations in benign breast fibroepithelial lesions in adolescents and young adults.

Pareja F, Da Cruz Paula A, Murray MP, Hoang T, Gularte-Mérida R, Brown D, da Silva EM, Sebastiao APM, Giri DD, Weigelt B, Reis-Filho JS, Brogi E.

J Clin Pathol. 2019 Mar;72(3):258-262. doi: 10.1136/jclinpath-2018-205570. Epub 2018 Nov 22.

14.

Analysis of mutational signatures in primary and metastatic endometrial cancer reveals distinct patterns of DNA repair defects and shifts during tumor progression.

Ashley CW, Da Cruz Paula A, Kumar R, Mandelker D, Pei X, Riaz N, Reis-Filho JS, Weigelt B.

Gynecol Oncol. 2019 Jan;152(1):11-19. doi: 10.1016/j.ygyno.2018.10.032. Epub 2018 Nov 8.

PMID:
30415991
15.

Reliability of Whole-Exome Sequencing for Assessing Intratumor Genetic Heterogeneity.

Shi W, Ng CKY, Lim RS, Jiang T, Kumar S, Li X, Wali VB, Piscuoglio S, Gerstein MB, Chagpar AB, Weigelt B, Pusztai L, Reis-Filho JS, Hatzis C.

Cell Rep. 2018 Nov 6;25(6):1446-1457. doi: 10.1016/j.celrep.2018.10.046.

16.

The role of a monoclonal antibody 11C8B1 as a diagnostic marker of IDH2-mutated sinonasal undifferentiated carcinoma.

Dogan S, Frosina D, Fayad M, de Oliveira TB, Alemar B, Rosenblum M, Tang LH, Hameed M, Xu B, Ghossein RA, Chute DJ, Weigelt B, Jungbluth AA.

Mod Pathol. 2019 Feb;32(2):205-215. doi: 10.1038/s41379-018-0126-3. Epub 2018 Sep 11.

PMID:
30206411
17.

The Genomic Landscape of Endocrine-Resistant Advanced Breast Cancers.

Razavi P, Chang MT, Xu G, Bandlamudi C, Ross DS, Vasan N, Cai Y, Bielski CM, Donoghue MTA, Jonsson P, Penson A, Shen R, Pareja F, Kundra R, Middha S, Cheng ML, Zehir A, Kandoth C, Patel R, Huberman K, Smyth LM, Jhaveri K, Modi S, Traina TA, Dang C, Zhang W, Weigelt B, Li BT, Ladanyi M, Hyman DM, Schultz N, Robson ME, Hudis C, Brogi E, Viale A, Norton L, Dickler MN, Berger MF, Iacobuzio-Donahue CA, Chandarlapaty S, Scaltriti M, Reis-Filho JS, Solit DB, Taylor BS, Baselga J.

Cancer Cell. 2018 Sep 10;34(3):427-438.e6. doi: 10.1016/j.ccell.2018.08.008.

PMID:
30205045
18.

Lobular Carcinomas In Situ Display Intralesion Genetic Heterogeneity and Clonal Evolution in the Progression to Invasive Lobular Carcinoma.

Lee JY, Schizas M, Geyer FC, Selenica P, Piscuoglio S, Sakr RA, Ng CKY, Carniello JVS, Towers R, Giri DD, de Andrade VP, Papanastasiou AD, Viale A, Harris RS, Solit DB, Weigelt B, Reis-Filho JS, King TA.

Clin Cancer Res. 2019 Jan 15;25(2):674-686. doi: 10.1158/1078-0432.CCR-18-1103. Epub 2018 Sep 5.

PMID:
30185420
19.

Loss-of-function mutations in ATP6AP1 and ATP6AP2 in granular cell tumors.

Pareja F, Brandes AH, Basili T, Selenica P, Geyer FC, Fan D, Da Cruz Paula A, Kumar R, Brown DN, Gularte-Mérida R, Alemar B, Bi R, Lim RS, de Bruijn I, Fujisawa S, Gardner R, Feng E, Li A, da Silva EM, Lozada JR, Blecua P, Cohen-Gould L, Jungbluth AA, Rakha EA, Ellis IO, Edelweiss MIA, Palazzo J, Norton L, Hollmann T, Edelweiss M, Rubin BP, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 Aug 30;9(1):3533. doi: 10.1038/s41467-018-05886-y.

20.

Clinical Utility of Prospective Molecular Characterization in Advanced Endometrial Cancer.

Soumerai TE, Donoghue MTA, Bandlamudi C, Srinivasan P, Chang MT, Zamarin D, Cadoo KA, Grisham RN, O'Cearbhaill RE, Tew WP, Konner JA, Hensley ML, Makker V, Sabbatini P, Spriggs DR, Troso-Sandoval TA, Charen AS, Friedman C, Gorsky M, Schweber SJ, Middha S, Murali R, Chiang S, Park KJ, Soslow RA, Ladanyi M, Li BT, Mueller J, Weigelt B, Zehir A, Berger MF, Abu-Rustum NR, Aghajanian C, DeLair DF, Solit DB, Taylor BS, Hyman DM.

Clin Cancer Res. 2018 Dec 1;24(23):5939-5947. doi: 10.1158/1078-0432.CCR-18-0412. Epub 2018 Aug 1.

PMID:
30068706
21.

Massively parallel sequencing analysis of mucinous ovarian carcinomas: genomic profiling and differential diagnoses.

Mueller JJ, Schlappe BA, Kumar R, Olvera N, Dao F, Abu-Rustum N, Aghajanian C, DeLair D, Hussein YR, Soslow RA, Levine DA, Weigelt B.

Gynecol Oncol. 2018 Jul;150(1):127-135. doi: 10.1016/j.ygyno.2018.05.008. Epub 2018 May 22.

22.

Genetic heterogeneity and actionable mutations in HER2-positive primary breast cancers and their brain metastases.

De Mattos-Arruda L, Ng CKY, Piscuoglio S, Gonzalez-Cao M, Lim RS, De Filippo MR, Fusco N, Schultheis AM, Ortiz C, Viteri S, Arias A, Macedo GS, Oliveira M, Gomez P, Teixidó C, Nuciforo P, Peg V, Saura C, Ramon Y Cajal S, Casas FT, Weigelt B, Cortes J, Seoane J, Reis-Filho JS.

Oncotarget. 2018 Apr 17;9(29):20617-20630. doi: 10.18632/oncotarget.25041. eCollection 2018 Apr 17.

23.

Recurrent hotspot mutations in HRAS Q61 and PI3K-AKT pathway genes as drivers of breast adenomyoepitheliomas.

Geyer FC, Li A, Papanastasiou AD, Smith A, Selenica P, Burke KA, Edelweiss M, Wen HC, Piscuoglio S, Schultheis AM, Martelotto LG, Pareja F, Kumar R, Brandes A, Fan D, Basili T, Da Cruz Paula A, Lozada JR, Blecua P, Muenst S, Jungbluth AA, Foschini MP, Wen HY, Brogi E, Palazzo J, Rubin BP, Ng CKY, Norton L, Varga Z, Ellis IO, Rakha EA, Chandarlapaty S, Weigelt B, Reis-Filho JS.

Nat Commun. 2018 May 8;9(1):1816. doi: 10.1038/s41467-018-04128-5.

24.

Capturing intra-tumor genetic heterogeneity by de novo mutation profiling of circulating cell-free tumor DNA: a proof-of-principle.

Mattos-Arruda L, Weigelt B, Cortes J, Won HH, Ng CKY, Nuciforo P, Bidard FC, Aura C, Saura C, Peg V, Piscuoglio S, Oliveira M, Smolders Y, Patel P, Norton L, Tabernero J, Berger MF, Seoane J, Reis-Filho JS.

Ann Oncol. 2018 Nov 1;29(11):2268. doi: 10.1093/annonc/mdx804. No abstract available.

PMID:
29718117
25.

Mutation Profiling of Key Cancer Genes in Primary Breast Cancers and Their Distant Metastases.

Schrijver WAME, Selenica P, Lee JY, Ng CKY, Burke KA, Piscuoglio S, Berman SH, Reis-Filho JS, Weigelt B, van Diest PJ, Moelans CB.

Cancer Res. 2018 Jun 15;78(12):3112-3121. doi: 10.1158/0008-5472.CAN-17-2310. Epub 2018 Apr 3.

26.

Solid papillary breast carcinomas resembling the tall cell variant of papillary thyroid neoplasms (solid papillary carcinomas with reverse polarity) harbour recurrent mutations affecting IDH2 and PIK3CA: a validation cohort.

Lozada JR, Basili T, Pareja F, Alemar B, Paula ADC, Gularte-Merida R, Giri DD, Querzoli P, Cserni G, Rakha EA, Foschini MP, Reis-Filho JS, Brogi E, Weigelt B, Geyer FC.

Histopathology. 2018 Aug;73(2):339-344. doi: 10.1111/his.13522. Epub 2018 Jun 1.

PMID:
29603332
27.

ESR1 and endocrine therapy resistance: more than just mutations.

Piscuoglio S, Ng CKY, Weigelt B, Chandarlapaty S, Reis-Filho JS.

Ann Oncol. 2018 Apr 1;29(4):787-789. doi: 10.1093/annonc/mdy081. No abstract available.

28.

The Landscape of Somatic Genetic Alterations in Breast Cancers From ATM Germline Mutation Carriers.

Weigelt B, Bi R, Kumar R, Blecua P, Mandelker DL, Geyer FC, Pareja F, James PA; kConFab Investigators, Couch FJ, Eccles DM, Blows F, Pharoah P, Li A, Selenica P, Lim RS, Jayakumaran G, Waddell N, Shen R, Norton L, Wen HY, Powell SN, Riaz N, Robson ME, Reis-Filho JS, Chenevix-Trench G.

J Natl Cancer Inst. 2018 Sep 1;110(9):1030-1034. doi: 10.1093/jnci/djy028.

29.

The value of cell-free DNA for molecular pathology.

Stewart CM, Kothari PD, Mouliere F, Mair R, Somnay S, Benayed R, Zehir A, Weigelt B, Dawson SJ, Arcila ME, Berger MF, Tsui DW.

J Pathol. 2018 Apr;244(5):616-627. doi: 10.1002/path.5048. Epub 2018 Mar 12. Review.

PMID:
29380875
30.

Genomic and transcriptomic heterogeneity in metaplastic carcinomas of the breast.

Piscuoglio S, Ng CKY, Geyer FC, Burke KA, Cowell CF, Martelotto LG, Natrajan R, Popova T, Maher CA, Lim RS, Bruijn I, Mariani O, Norton L, Vincent-Salomon A, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2017 Dec 1;3:48. doi: 10.1038/s41523-017-0048-0. eCollection 2017.

31.

MYBL1 rearrangements and MYB amplification in breast adenoid cystic carcinomas lacking the MYB-NFIB fusion gene.

Kim J, Geyer FC, Martelotto LG, Ng CK, Lim RS, Selenica P, Li A, Pareja F, Fusco N, Edelweiss M, Kumar R, Gularte-Merida R, Forbes AN, Khurana E, Mariani O, Badve S, Vincent-Salomon A, Norton L, Reis-Filho JS, Weigelt B.

J Pathol. 2018 Feb;244(2):143-150. doi: 10.1002/path.5006. Epub 2017 Dec 28.

32.

Low PTEN levels and PIK3CA mutations predict resistance to neoadjuvant lapatinib and trastuzumab without chemotherapy in patients with HER2 over-expressing breast cancer.

Rimawi MF, De Angelis C, Contreras A, Pareja F, Geyer FC, Burke KA, Herrera S, Wang T, Mayer IA, Forero A, Nanda R, Goetz MP, Chang JC, Krop IE, Wolff AC, Pavlick AC, Fuqua SAW, Gutierrez C, Hilsenbeck SG, Li MM, Weigelt B, Reis-Filho JS, Kent Osborne C, Schiff R.

Breast Cancer Res Treat. 2018 Feb;167(3):731-740. doi: 10.1007/s10549-017-4533-9. Epub 2017 Nov 7.

33.

Phyllodes tumors with and without fibroadenoma-like areas display distinct genomic features and may evolve through distinct pathways.

Pareja F, Geyer FC, Kumar R, Selenica P, Piscuoglio S, Ng CKY, Burke KA, Edelweiss M, Murray MP, Brogi E, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2017 Oct 12;3:40. doi: 10.1038/s41523-017-0042-6. eCollection 2017.

34.

Pan-cancer analysis of bi-allelic alterations in homologous recombination DNA repair genes.

Riaz N, Blecua P, Lim RS, Shen R, Higginson DS, Weinhold N, Norton L, Weigelt B, Powell SN, Reis-Filho JS.

Nat Commun. 2017 Oct 11;8(1):857. doi: 10.1038/s41467-017-00921-w.

35.

Reply to Rosen.

Reis-Filho JS, Geyer FC, Weigelt B, Rakha EA, Ellis IO, Schnitt SJ.

Mod Pathol. 2017 Oct;30(10):1505-1506. doi: 10.1038/modpathol.2017.70. No abstract available.

36.

Contralateral breast cancers: Independent cancers or metastases?

Begg CB, Ostrovnaya I, Geyer FC, Papanastasiou AD, Ng CKY, Sakr RA, Bernstein JL, Burke KA, King TA, Piscuoglio S, Mauguen A, Orlow I, Weigelt B, Seshan VE, Morrow M, Reis-Filho JS.

Int J Cancer. 2018 Jan 15;142(2):347-356. doi: 10.1002/ijc.31051. Epub 2017 Sep 28.

37.

Diverse BRCA1 and BRCA2 Reversion Mutations in Circulating Cell-Free DNA of Therapy-Resistant Breast or Ovarian Cancer.

Weigelt B, Comino-Méndez I, de Bruijn I, Tian L, Meisel JL, García-Murillas I, Fribbens C, Cutts R, Martelotto LG, Ng CKY, Lim RS, Selenica P, Piscuoglio S, Aghajanian C, Norton L, Murali R, Hyman DM, Borsu L, Arcila ME, Konner J, Reis-Filho JS, Greenberg RA, Robson ME, Turner NC.

Clin Cancer Res. 2017 Nov 1;23(21):6708-6720. doi: 10.1158/1078-0432.CCR-17-0544. Epub 2017 Aug 1.

38.

The Spectrum of Triple-Negative Breast Disease: High- and Low-Grade Lesions.

Geyer FC, Pareja F, Weigelt B, Rakha E, Ellis IO, Schnitt SJ, Reis-Filho JS.

Am J Pathol. 2017 Oct;187(10):2139-2151. doi: 10.1016/j.ajpath.2017.03.016. Epub 2017 Jul 20. Review.

39.

Triple-negative breast cancer: the importance of molecular and histologic subtyping, and recognition of low-grade variants.

Pareja F, Geyer FC, Marchiò C, Burke KA, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2016 Nov 16;2:16036. doi: 10.1038/npjbcancer.2016.36. eCollection 2016. Review.

40.

Massively parallel sequencing analysis of synchronous fibroepithelial lesions supports the concept of progression from fibroadenoma to phyllodes tumor.

Piscuoglio S, Geyer FC, Burke KA, Murray MP, Ng CK, Mota A, Marchio C, Berman SH, Norton L, Brogi E, Weigelt B, Reis-Filho JS.

NPJ Breast Cancer. 2016 Nov 16;2:16035. doi: 10.1038/npjbcancer.2016.35. eCollection 2016.

41.

The genetic landscape of endometrial clear cell carcinomas.

DeLair DF, Burke KA, Selenica P, Lim RS, Scott SN, Middha S, Mohanty AS, Cheng DT, Berger MF, Soslow RA, Weigelt B.

J Pathol. 2017 Oct;243(2):230-241. doi: 10.1002/path.4947. Epub 2017 Sep 5.

42.

Leiomyoma with bizarre nuclei: a morphological, immunohistochemical and molecular analysis of 31 cases.

Bennett JA, Weigelt B, Chiang S, Selenica P, Chen YB, Bialik A, Bi R, Schultheis AM, Lim RS, Ng CKY, Morales-Oyarvide V, Young RH, Reuter VE, Soslow RA, Oliva E.

Mod Pathol. 2017 Oct;30(10):1476-1488. doi: 10.1038/modpathol.2017.56. Epub 2017 Jun 30.

43.

Myxoid fibroadenomas differ from conventional fibroadenomas: a hypothesis-generating study.

Lozada JR, Burke KA, Maguire A, Pareja F, Lim RS, Kim J, Gularte-Merida R, Murray MP, Brogi E, Weigelt B, Reis-Filho JS, Geyer FC.

Histopathology. 2017 Oct;71(4):626-634. doi: 10.1111/his.13258. Epub 2017 Jul 5.

44.

HER2 Reactivation through Acquisition of the HER2 L755S Mutation as a Mechanism of Acquired Resistance to HER2-targeted Therapy in HER2+ Breast Cancer.

Xu X, De Angelis C, Burke KA, Nardone A, Hu H, Qin L, Veeraraghavan J, Sethunath V, Heiser LM, Wang N, Ng CKY, Chen ES, Renwick A, Wang T, Nanda S, Shea M, Mitchell T, Rajendran M, Waters I, Zabransky DJ, Scott KL, Gutierrez C, Nagi C, Geyer FC, Chamness GC, Park BH, Shaw CA, Hilsenbeck SG, Rimawi MF, Gray JW, Weigelt B, Reis-Filho JS, Osborne CK, Schiff R.

Clin Cancer Res. 2017 Sep 1;23(17):5123-5134. doi: 10.1158/1078-0432.CCR-16-2191. Epub 2017 May 9.

45.

Genetic analysis of a morphologically heterogeneous ovarian endometrioid carcinoma.

Geyer FC, Pareja F, Burke KA, Schultheis AM, Hussein YR, Ye J, De Filippo MR, Marchio C, Macedo GS, Piscuoglio S, Lim RS, Toy E, Murali R, Jungbluth AA, Reis-Filho JS, Soslow RA, Weigelt B.

Histopathology. 2017 Sep;71(3):480-487. doi: 10.1111/his.13240. Epub 2017 Jun 16.

46.

Genetic Heterogeneity in Therapy-Naïve Synchronous Primary Breast Cancers and Their Metastases.

Ng CKY, Bidard FC, Piscuoglio S, Geyer FC, Lim RS, de Bruijn I, Shen R, Pareja F, Berman SH, Wang L, Pierga JY, Vincent-Salomon A, Viale A, Norton L, Sigal B, Weigelt B, Cottu P, Reis-Filho JS.

Clin Cancer Res. 2017 Aug 1;23(15):4402-4415. doi: 10.1158/1078-0432.CCR-16-3115. Epub 2017 Mar 28.

47.

Compromised BRCA1-PALB2 interaction is associated with breast cancer risk.

Foo TK, Tischkowitz M, Simhadri S, Boshari T, Zayed N, Burke KA, Berman SH, Blecua P, Riaz N, Huo Y, Ding YC, Neuhausen SL, Weigelt B, Reis-Filho JS, Foulkes WD, Xia B.

Oncogene. 2017 Jul 20;36(29):4161-4170. doi: 10.1038/onc.2017.46. Epub 2017 Mar 20.

48.

Bi-allelic alterations in DNA repair genes underpin homologous recombination DNA repair defects in breast cancer.

Mutter RW, Riaz N, Ng CK, Delsite R, Piscuoglio S, Edelweiss M, Martelotto LG, Sakr RA, King TA, Giri DD, Drobnjak M, Brogi E, Bindra R, Bernheim G, Lim RS, Blecua P, Desrichard A, Higginson D, Towers R, Jiang R, Lee W, Weigelt B, Reis-Filho JS, Powell SN.

J Pathol. 2017 Jun;242(2):165-177. doi: 10.1002/path.4890. Epub 2017 Apr 27.

49.

A novel representation of inter-site tumour heterogeneity from pre-treatment computed tomography textures classifies ovarian cancers by clinical outcome.

Vargas HA, Veeraraghavan H, Micco M, Nougaret S, Lakhman Y, Meier AA, Sosa R, Soslow RA, Levine DA, Weigelt B, Aghajanian C, Hricak H, Deasy J, Snyder A, Sala E.

Eur Radiol. 2017 Sep;27(9):3991-4001. doi: 10.1007/s00330-017-4779-y. Epub 2017 Mar 13.

50.

Genetic analysis of uterine adenosarcomas and phyllodes tumors of the breast.

Geyer FC, Burke KA, Piscuoglio S, Ng CKY, Papanastasiou AD, Marchiò C, Selenica P, Edelweiss M, Murray MP, Brogi E, Soslow RA, Rubin BP, Norton L, Reis-Filho JS, Weigelt B.

Mol Oncol. 2017 Aug;11(8):913-926. doi: 10.1002/1878-0261.12049. Epub 2017 May 16.

Supplemental Content

Loading ...
Support Center